Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s EfficacyPRNewsWire · Sep 23, 2026
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in ProceedsPRNewsWire · Sep 16, 2026
5 Small Drug Stocks Poised to Benefit From a Biotech RecoveryZacks Investment Research · Sep 14, 2026
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities CommissionPRNewsWire · Sep 10, 2026
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment ConferencePRNewsWire · Sep 9, 2026
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research · Aug 25, 2026Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.09 | -$0.04 | Beat |
| May 11, 2026 | -$0.07 | -$0.07 | Beat |
| Mar 30, 2026 | -$0.09 | -$0.05 | Beat |
| Nov 13, 2025 | -$0.09 | -$0.09 | Beat |
| Aug 14, 2025 | -$0.11 | -$0.07 | Beat |
| May 14, 2025 | -$0.09 | -$0.07 | Beat |